Verastem (VSTM) Competitors $9.54 +0.10 (+1.06%) Closing price 04:00 PM EasternExtended Trading$9.56 +0.02 (+0.21%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. MNKD, BCRX, CLDX, NVAX, INVA, OPK, DVAX, ZBIO, GERN, and RIGLShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors MannKind BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva OPKO Health Dynavax Technologies Zenas BioPharma Geron Rigel Pharmaceuticals Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability. Is VSTM or MNKD more profitable? MannKind has a net margin of 10.87% compared to Verastem's net margin of 0.00%. MannKind's return on equity of -32.60% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -2,003.62% -119.85% MannKind 10.87%-32.60%7.81% Do analysts rate VSTM or MNKD? Verastem presently has a consensus target price of $13.29, suggesting a potential upside of 39.26%. MannKind has a consensus target price of $11.17, suggesting a potential upside of 99.05%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00MannKind 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals and insiders believe in VSTM or MNKD? 88.4% of Verastem shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 2.1% of Verastem shares are held by company insiders. Comparatively, 2.7% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, VSTM or MNKD? Verastem has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Which has better earnings & valuation, VSTM or MNKD? MannKind has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$10K58,709.16-$130.64M-$3.28-2.91MannKind$285.50M6.03$27.59M$0.1151.00 Does the media favor VSTM or MNKD? In the previous week, Verastem had 1 more articles in the media than MannKind. MarketBeat recorded 10 mentions for Verastem and 9 mentions for MannKind. MannKind's average media sentiment score of 0.78 beat Verastem's score of 0.54 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMannKind beats Verastem on 12 of the 16 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$580.99M$3.12B$5.76B$10.29BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-2.9121.2276.8626.97Price / Sales58,709.16462.32540.67127.61Price / CashN/A45.3237.1760.63Price / Book-14.689.6913.836.37Net Income-$130.64M-$52.92M$3.29B$271.46M7 Day Performance2.03%1.44%0.93%2.35%1 Month Performance19.70%6.03%5.31%7.78%1 Year Performance252.03%12.89%84.25%32.27% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.0474 of 5 stars$9.54+1.1%$13.29+39.3%+239.6%$580.99M$10K-2.9150MNKDMannKind4.3965 of 5 stars$5.38-3.4%$11.17+107.6%-17.8%$1.71B$285.50M48.91400Analyst ForecastInsider TradeShort Interest ↓BCRXBioCryst Pharmaceuticals4.2953 of 5 stars$7.70-2.7%$16.70+116.9%-2.8%$1.66B$450.71M-42.78530Positive NewsCLDXCelldex Therapeutics2.1964 of 5 stars$24.50+0.2%$46.67+90.5%-40.7%$1.62B$7.02M-8.14150Positive NewsAnalyst ForecastNVAXNovavax4.2316 of 5 stars$8.08+1.3%$14.29+76.8%-35.1%$1.30B$682.16M3.541,990INVAInnoviva4.7431 of 5 stars$19.55+0.9%$42.75+118.7%-1.7%$1.22B$358.71M63.07100Positive NewsShort Interest ↓OPKOPKO Health4.3865 of 5 stars$1.38-1.4%$2.75+99.3%-16.3%$1.11B$713.10M-5.522,997DVAXDynavax Technologies4.4106 of 5 stars$9.36-0.5%$24.33+160.0%-15.0%$1.10B$277.25M-20.35350Positive NewsZBIOZenas BioPharma1.1591 of 5 stars$21.95+8.5%$36.67+67.0%N/A$851.89M$5M-6.18N/AGERNGeron3.18 of 5 stars$1.27flat$3.79+198.1%-72.1%$810.28M$76.99M-9.7770Positive NewsRIGLRigel Pharmaceuticals2.535 of 5 stars$37.30-1.7%$38.20+2.4%+150.1%$680.90M$179.28M6.89160News CoveragePositive News Related Companies and Tools Related Companies MannKind Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Zenas BioPharma Alternatives Geron Alternatives Rigel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Plan Could Spark Chaos—Gold Protects YouAn insider close to the administration just warned of a radical Trump plan that could shake markets and ignite...Reagan Gold Group | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
